D. Boral Capital Reaffirms “Buy” Rating for VolitionRx (NYSE:VNRX)

D. Boral Capital reaffirmed their buy rating on shares of VolitionRx (NYSE:VNRX) in a research note released on Tuesday morning,Benzinga reports. They currently have a $5.00 target price on the stock.

Other equities analysts have also recently issued reports about the company. StockNews.com started coverage on VolitionRx in a research report on Tuesday. They issued a “sell” rating on the stock. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

VolitionRx Trading Up 5.1 %

VNRX stock opened at $0.61 on Tuesday. The stock has a market capitalization of $56.60 million, a PE ratio of -1.70 and a beta of 1.09. VolitionRx has a 12-month low of $0.43 and a 12-month high of $1.10. The stock’s 50 day simple moving average is $0.61 and its 200 day simple moving average is $0.65.

Insider Buying and Selling at VolitionRx

In related news, CEO Cameron John Reynolds bought 139,811 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was acquired at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the purchase, the chief executive officer now owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Guy Archibald Innes bought 174,764 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were bought at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the purchase, the director now owns 617,085 shares in the company, valued at approximately $351,738.45. The trade was a 39.51 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 358,266 shares of company stock worth $204,212. Insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC purchased a new stake in shares of VolitionRx in the 4th quarter worth $36,000. Lagoda Investment Management L.P. increased its stake in shares of VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Northern Trust Corp increased its stake in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares in the last quarter. Two Sigma Securities LLC purchased a new stake in shares of VolitionRx in the 4th quarter worth $29,000. Finally, Geode Capital Management LLC increased its stake in shares of VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares in the last quarter. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.